DAIICHI SANKYO – ASTRAZENECA RESEARCH GRANT ON ANTIBODY DRUG CONJUGATES

LUNG CANCER RESEARCH FOUNDATION (LCRF)

Object

Topic: Lung Cancer.

Destination: Projects focused on one or more of the following topics that support research studies to develop further understanding of the mechanism of action and biomarkers for TROP2 directed ADCs in lung cancer and HER2 directed ADCs in HER2 mutant NSCLC and primary and acquired resistance to TROP2 directed and HER2 directed ADCs.

Budget: Maximum $135,000/year.

Duration: 2 years.

Are you interested in this call?

Are you interested?

Fill out the form below to receive more information: